Table 1.
Comparison of Baseline Characteristics of 192 Hospitalized Children With Mild to Moderate Clostridioides difficile Infection Treated With Oral Metronidazole Versus Oral Vancomycin in the Full Cohort and Propensity-Score Weighted Cohort
| Full Cohort | Weighted Cohorta | |||||||
|---|---|---|---|---|---|---|---|---|
| Metronidazole (n = 141, 73 %) | Vancomycin (n = 51, 27 %) | P value | Standardized difference | Metronidazole (n = 142, 74 %) | Vancomycin (n = 50, 26%) | P value | Standardized difference | |
| Age, median (interquartile range) | 8 years (4–13) | 9 years (4–15) | .242 | 0.188 | 8 years (8–13) | 9 years (4–15) | .212 | 0.215 |
| Male, n (%) | 76 (53.9) | 27 (52.9) | .906 | 0.019 | 77 (54.1) | 26 (51.2) | .740 | 0.058 |
| Race/ethnicity, n (%) | ||||||||
| Black | 36 (25.5) | 11 (21.6) | .573 | -0.093 | 35 (24.6) | 11 (20.9) | .614 | -0.087 |
| White | 77 (54.6) | 35 (68.6) | .082 | 0.289 | 81 (56.9) | 34 (68.0) | .191 | 0.231 |
| Latino | 7 (5.0) | 2 (3.9) | .763 | -0.050 | 6 (4.4) | 2 (3.5) | .783 | -0.045 |
| Asian | 8 (5.7) | 0 | .082 | -0.346 | 8 (5.7) | 0 | .094 | -0.347 |
| Other | 13 (9.2) | 3 (5.9) | .460 | -0.126 | 12 (8.5) | 4 (7.5) | .855 | -0.034 |
| Previous episode of Clostridioides difficile infection within past 2 years, n (%)b | 14 (9.9) | 15 (29.4) | .001 | 0.502 | 23 (15.9) | 8 (16.1) | .967 | 0.006 |
| Pre-existing medical conditions, n (%) | ||||||||
| Chemotherapy within the past 6 months | 29 (20.6) | 6 (11.8) | .163 | -0.239 | 25 (17.9) | 8 (16.2) | .823 | -0.043 |
| Hematopoietic stem cell transplant in past 12 months | 15 (10.6) | 5 (9.8) | .867 | -0.027 | 15 (10.2) | 5 (10.5) | .955 | 0.010 |
| Solid organ transplant recipient | 8 (5.7) | 3 (5.9) | .956 | 0.009 | 8 (5.7) | 3 (5.3) | .917 | -0.018 |
| Crohn’s disease | 10 (7.1) | 5 (9.8) | .536 | 0.097 | 11 (8.0) | 4 (8.1) | .989 | 0.002 |
| Ulcerative colitis | 8 (5.7) | 6 (11.7) | .152 | 0.215 | 11 (7.8) | 4 (8.0) | .970 | 0.006 |
| Surveillance categoriesc | ||||||||
| Community-onset | 35 (24.8) | 18 (35.3) | .152 | 0.228 | 41 (28.6) | 15 (30.4) | .813 | 0.040 |
| Community-onset healthcare, facility-associated | 48 (34.0) | 15 (29.4) | .546 | -0.099 | 45 (31.9) | 15 (30.0) | .817 | -0.041 |
| Healthcare facility-onset | 58 (41.1) | 18 (35.3) | .465 | -0.120 | 56 (39.5) | 20 (39.6) | .993 | 0.001 |
aWeighted cohort numbers rounded to whole numbers.
bChildren who experienced a previous Clostridioides difficile infection episode within the past 3 months were excluded.